merged_eli-lilly-zepbound-price.txt
<question_number>1</question_number>
<answer>Eli Lilly's vials are FDA-approved, offering a safer alternative to compounded drugs with less oversight.</answer>

<question_number>2</question_number>
<answer>By providing a direct, lower-cost, FDA-approved option through its own telehealth platform, bypassing third-party compounders.</answer>

<question_number>3</question_number>
<answer>Compounded drugs lack FDA oversight for safety, quality, and effectiveness.</answer>

<question_number>4</question_number>
<answer>To compete with compounders by offering a cheaper, safer alternative, even if it reduces sales of its higher-priced pens.</answer>

<question_number>5</question_number>
<answer>The FDA's shortage list allows compounding pharmacies to legally produce tirzepatide alternatives; Lilly challenges this by increasing supply.</answer>

<question_number>6</question_number>
<answer>Reflects a shift toward direct-to-consumer sales, cutting out third-party supply chain costs for "transparent pricing."</answer>

<question_number>7</question_number>
<answer>Older Medicare patients may face higher risks (e.g., muscle loss) without coverage, yet may still seek Lilly's vials.</answer>

<question_number>8</question_number>
<answer>Patients may perceive Lilly's FDA-approved vials as safer than unregulated compounded alternatives.</answer>

<question_number>9</question_number>
<answer>Being listed as "in shortage" by the FDA.</answer>

<question_number>10</question_number>
<answer>Lower pricing to signal competition and reclaim market share from compounders.</answer>